SGCB and Duchenne muscular dystrophy: The implication of understanding the NO-sGC-PKG pathway would help to design new therapeutic strategies in muscle diseases, such as Duchenne muscular dystrophy, where the correct localization and expression of nNOS is impaired, being replaced by the expression of iNOS hindering correct function of NO (Mosqueira et al., 2013).